ArticleMolecular cancer therapeutics2024

XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies.

Ekta Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.